ATE180833T1 - Cytokinsynthesehemmender faktor (csif) und verfahren zur anwendung - Google Patents

Cytokinsynthesehemmender faktor (csif) und verfahren zur anwendung

Info

Publication number
ATE180833T1
ATE180833T1 AT90911213T AT90911213T ATE180833T1 AT E180833 T1 ATE180833 T1 AT E180833T1 AT 90911213 T AT90911213 T AT 90911213T AT 90911213 T AT90911213 T AT 90911213T AT E180833 T1 ATE180833 T1 AT E180833T1
Authority
AT
Austria
Prior art keywords
csif
application
synthesis inhibitory
cytokine synthesis
inhibitory factor
Prior art date
Application number
AT90911213T
Other languages
English (en)
Inventor
Timothy R Mosmann
Kevin W Moore
Martha W Bond
Paulo J M Vieira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE180833T1 publication Critical patent/ATE180833T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT90911213T 1989-06-28 1990-06-28 Cytokinsynthesehemmender faktor (csif) und verfahren zur anwendung ATE180833T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37266789A 1989-06-28 1989-06-28
US45395189A 1989-12-20 1989-12-20

Publications (1)

Publication Number Publication Date
ATE180833T1 true ATE180833T1 (de) 1999-06-15

Family

ID=27005854

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90911213T ATE180833T1 (de) 1989-06-28 1990-06-28 Cytokinsynthesehemmender faktor (csif) und verfahren zur anwendung

Country Status (22)

Country Link
EP (2) EP0567450B1 (de)
JP (1) JP2813063B2 (de)
KR (1) KR0183035B1 (de)
CN (3) CN1318589C (de)
AT (1) ATE180833T1 (de)
AU (1) AU635058B2 (de)
CA (1) CA2062763C (de)
CS (1) CS414591A3 (de)
DE (1) DE69033143T2 (de)
DK (1) DK0567450T3 (de)
ES (1) ES2132068T3 (de)
FI (1) FI107926B (de)
GR (1) GR3030404T3 (de)
HK (3) HK1008834A1 (de)
HU (1) HU216310B (de)
IL (1) IL94878A (de)
NO (1) NO301718B1 (de)
NZ (1) NZ234291A (de)
PT (1) PT94514B (de)
SG (1) SG52282A1 (de)
TW (1) TW218383B (de)
WO (1) WO1991000349A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
DE69203443T2 (de) * 1991-01-16 1995-12-07 Schering Corp Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.
SK279556B6 (sk) * 1991-01-16 1998-12-02 Schering Corporation Liečivo na liečenie nádorov pacienta
US6106823A (en) * 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
DK0600970T3 (da) * 1991-08-06 2000-05-29 Schering Corp Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit
US6277635B1 (en) 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
EP0629130A1 (de) * 1992-03-04 1994-12-21 Schering Corporation Verwendung von interleukin-10 zur unterdrückung der graft versus host krankheit
US6884410B1 (en) 1992-03-04 2005-04-26 Schering Corporation Methods for modulating antigen-specific immune responses
AU3801193A (en) * 1992-03-20 1993-10-21 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
HU220103B (hu) * 1992-08-20 2001-10-28 Schering-Plough Corp. IL-10 új alkalmazása
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
JPH08501549A (ja) * 1992-09-18 1996-02-20 スケアリング コーポレイション Ｈｉｖ感染された患者におけるｔヘルパー細胞の免疫担当能力の回復
EP0662837B1 (de) * 1992-10-01 1999-05-19 Schering Corporation Verwendung der il-10 zur verhinderung des insulin-abhängigen diabetes mellitus
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
WO1994017773A2 (en) * 1993-02-01 1994-08-18 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
CZ23396A3 (en) * 1993-07-26 1996-05-15 Schering Corp Antagonists and agonists of human interleukin-10
US5650060A (en) * 1994-01-28 1997-07-22 Minnesota Mining And Manufacturing Company Ionically conductive agent, system for cathodic protection of galvanically active metals, and method and apparatus for using same
AP690A (en) * 1994-07-05 1998-10-16 Steeno Res Group A/S Immunomodulators based on a polypeptide other than human interleukin 10.
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
CN100389126C (zh) * 1995-12-13 2008-05-21 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
WO1997038695A1 (en) * 1996-04-17 1997-10-23 Prendergast Patrick T Dhea combination therapy
AU722570B2 (en) * 1996-09-06 2000-08-03 Schering Corporation Method for lowering cholesterol levels
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US6465176B1 (en) * 1998-10-02 2002-10-15 Message Pharmaceuticals, Inc. Method for identifying compounds RNA/RNA binding protein interactions
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
KR20020091170A (ko) 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
WO2011159881A2 (en) 2010-06-16 2011-12-22 Allergan, Inc. Il-10 and methods of treating ocular and other diseases
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2018106959A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183931A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE62650B1 (en) * 1989-08-04 1995-02-22 David & Sons Ltd Dispensing apparatus
ES2064082T3 (es) * 1989-12-20 1995-01-16 Schering Corp Proteinas bcrf1 como inhibidores de interferon-gamma.

Also Published As

Publication number Publication date
EP0405980A1 (de) 1991-01-02
NO915115L (no) 1992-02-26
KR0183035B1 (ko) 1999-04-01
CA2062763A1 (en) 1990-12-29
FI107926B (fi) 2001-10-31
HK1040531B (zh) 2008-01-11
IL94878A (en) 2003-01-12
NZ234291A (en) 1992-11-25
CN1317569A (zh) 2001-10-17
DE69033143T2 (de) 1999-10-21
HU906705D0 (en) 1992-03-30
CN1051393A (zh) 1991-05-15
HK1008834A1 (en) 1999-05-21
AU6077090A (en) 1991-01-17
FI916126A0 (fi) 1991-12-27
ES2132068T3 (es) 1999-08-16
AU635058B2 (en) 1993-03-11
EP0567450A1 (de) 1993-11-03
JPH04502560A (ja) 1992-05-14
CN1198642C (zh) 2005-04-27
NO915115D0 (no) 1991-12-27
CN1318589C (zh) 2007-05-30
CA2062763C (en) 2010-01-05
HK1040493A1 (en) 2002-06-14
SG52282A1 (en) 1998-09-28
PT94514A (pt) 1991-04-18
HU216310B (hu) 1999-06-28
DE69033143D1 (de) 1999-07-08
KR920701437A (ko) 1992-08-11
WO1991000349A1 (en) 1991-01-10
CS414591A3 (en) 1992-12-16
HK1040493B (zh) 2005-12-16
EP0567450B1 (de) 1999-06-02
HK1040531A1 (en) 2002-06-14
IL94878A0 (en) 1991-04-15
CN1317343A (zh) 2001-10-17
HUT61048A (en) 1992-11-30
GR3030404T3 (en) 1999-09-30
JP2813063B2 (ja) 1998-10-22
PT94514B (pt) 1998-02-27
NO301718B1 (no) 1997-12-01
TW218383B (de) 1994-01-01
DK0567450T3 (da) 1999-12-13

Similar Documents

Publication Publication Date Title
ATE180833T1 (de) Cytokinsynthesehemmender faktor (csif) und verfahren zur anwendung
ES8602768A1 (es) Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas.
FI935585A0 (fi) Pyrrolopyrimidiner
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
ES2156852T3 (es) Citoquina mamifera, il-11.
CA2193993A1 (en) New hil-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
FR2609998B1 (fr) Nouvelles substances antioxydantes derivees d'acides amines
PT91750A (pt) Processo para a preparacao de factor de crescimento de celulas t auxiliares
NO922456D0 (no) Bcrf1-proteiner som inhibitorer av interferon-gamma
ATE86113T1 (de) Verfahren und zusammensetzungen fuer die behandlung von infektionen bei saeugetieren durch verwendung von arzneimitteln mit einem gehalt an hymenopteragift, eiweissartigen oder polypeptidkomponenten hiervon, oder analogen solcher eiweissartigen oder polypeptidkomponenten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time